Date published: 2026-4-1

1-800-457-3801

SCBT Portrait Logo
Seach Input

MrgB8 Inhibitors

MrgB8 inhibitors are a class of chemical compounds specifically designed to target and inhibit the function of MrgB8, a member of the Mas-related G-protein-coupled receptor (MRGPR) family. MrgB8 is expressed predominantly in sensory neurons, where it is thought to play a critical role in modulating nociceptive signals, or the sensory perception of potentially harmful stimuli such as pain. As a G-protein-coupled receptor (GPCR), MrgB8 mediates cellular responses to external stimuli by binding to specific ligands, which in turn activate intracellular signaling pathways that regulate neuronal excitability and sensitivity. This receptor is particularly involved in processing signals related to mechanical, thermal, or chemical stimuli, making it a key player in the modulation of pain pathways. Inhibition of MrgB8 disrupts these sensory processes, providing researchers with a valuable tool to study its specific role in neuronal signaling and pain perception.

In research, MrgB8 inhibitors are valuable for exploring the molecular mechanisms underlying sensory neuron activation and the modulation of pain signals. By blocking MrgB8 activity, scientists can investigate how inhibition affects the way sensory neurons respond to harmful stimuli, focusing on how disruptions in this receptor's function influence nociceptive pathways and the overall processing of pain. This inhibition allows researchers to study downstream effects on intracellular signaling cascades, receptor-ligand interactions, and broader networks that regulate sensory perception. Additionally, MrgB8 inhibitors can be used to explore the interaction between MrgB8 and other GPCRs within the nociceptive system, shedding light on the complex regulatory circuits involved in controlling pain sensitivity and sensory neuron behavior. Through these studies, the use of MrgB8 inhibitors enhances our understanding of the role of GPCR signaling in sensory physiology and provides insights into the intricate mechanisms that govern the perception of pain and other external stimuli.

SEE ALSO...

Product NameCAS #Catalog #QUANTITYPriceCitationsRATING

Pertussis Toxin (islet-activating protein)

70323-44-3sc-200837
50 µg
$451.00
3
(1)

An exotoxin that irreversibly inhibits G protein-coupled receptor signaling by ADP-ribosylation of the alpha subunit of the inhibitory G protein (Gi), which can affect MrgB8 activity.

Suramin sodium

129-46-4sc-507209
sc-507209F
sc-507209A
sc-507209B
sc-507209C
sc-507209D
sc-507209E
50 mg
100 mg
250 mg
1 g
10 g
25 g
50 g
$152.00
$214.00
$728.00
$2601.00
$10965.00
$21838.00
$41096.00
5
(1)

A polysulfonated naphthylurea that can non-selectively inhibit G protein-coupled receptor signaling by preventing receptor-G protein interactions.

Propranolol

525-66-6sc-507425
100 mg
$180.00
(0)

A non-selective beta-adrenergic receptor antagonist that can alter signaling in related GPCRs by competitive inhibition.

NF449

627034-85-9sc-478179
sc-478179A
sc-478179B
10 mg
25 mg
100 mg
$203.00
$469.00
$1509.00
1
(0)

A potent antagonist of Gs alpha subunit of G-proteins which can hinder GPCR-mediated signaling.

YM 254890

568580-02-9sc-507356
1 mg
$510.00
(0)

A cyclic depsipeptide that selectively inhibits Gq proteins, and may indirectly influence MrgB8 activity by modulating GPCR signaling pathways.

Scriptaid

287383-59-9sc-202807
sc-202807A
1 mg
5 mg
$64.00
$183.00
11
(2)

An inhibitor of Gq/11 alpha proteins that can suppress downstream signaling of related GPCRs.

ML 141

71203-35-5sc-362768
sc-362768A
5 mg
25 mg
$137.00
$512.00
7
(1)

A selective inhibitor of the Cdc42 GTPase, which interacts with G-protein signaling pathways and could modulate MrgB8 activity.

Gö 6983

133053-19-7sc-203432
sc-203432A
sc-203432B
1 mg
5 mg
10 mg
$105.00
$299.00
$474.00
15
(1)

A protein kinase C inhibitor that can disrupt GPCR-mediated signal transduction, possibly influencing MrgB8 function.

Gallein

2103-64-2sc-202631
50 mg
$85.00
20
(1)

A small molecule that blocks G-beta-gamma signaling, which is downstream of GPCR activation and could impact MrgB8.